An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
NCT01989884
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma
Interventions
DRUG:
Ortataxel
Sponsor
Mario Negri Institute for Pharmacological Research